← Eichor
Condition: Metastatic Castration Resistant Prostate Cancer Crpc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Castration Resistant Prostate Cancer Crpc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Phase 2 · 1 location(s) · Ebrahim S Delpassand · NCT06972628Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 8 location(s) · Acerand Therapeutics (Hong Kong) Limited · NCT06801236The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Phase 1 · 2 location(s) · Brigham and Women's Hospital · NCT06062745Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07007910A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular
Phase 1 · 83 location(s) · Pfizer · NCT03460977A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 24 location(s) · DualityBio Inc. · NCT05785741A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 107 location(s) · DualityBio Inc. · NCT05914116177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Radiopharm Theranostics, Ltd · NCT07189871Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Phase 1 · 1 location(s) · TechnoGenesys, Inc. · NCT06705686The COSMYC Trial (COmbined Suppression of MYC)
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06922318Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Pr
Phase 2 · 1 location(s) · Pengyuan Liu · NCT06249750A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants Wi
Phase 1 · 11 location(s) · IDEAYA Biosciences · NCT07540572A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 2 · 20 location(s) · Kyntra Bio · NCT06842498Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Adva
Phase 3 · 102 location(s) · Alliance for Clinical Trials in Oncology · NCT07200830A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Phase 1 · 15 location(s) · IDEAYA Biosciences · NCT07503808AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Phase 1/Phase 2 · 9 location(s) · Arsenal Biosciences, Inc. · NCT07285694Castrate Resistant Prostate Cancer Enhertu Therapy
Phase 2 · 1 location(s) · Washington D.C. Veterans Affairs Medical Center · NCT06610825A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Phase 1/Phase 2 · 7 location(s) · T.O.A.D. Oncology SA · NCT07258407Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Phase 2 · 3 location(s) · Edwin Posadas, MD · NCT05534646
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.